Tr1X Raises $75M in Series A Funding
Summary
Tr1X, a San Diego, CA-based biotechnology company focused on engineering cures for immune and inflammatory diseases, raised $75M in Series A funding. The round was led by The Column Group, with participation from NEVA SGR and Alexandria Ventures. The company intends to use the funds to enable immediate and expedited execution to advance its proprietary pipeline of first-of-their kind allogeneic engineered Treg and CAR-Treg cell therapies to treat major autoimmune diseases affecting millions of patients worldwide. Its pipeline of allogeneic cell therapies is being developed for diseases with high unmet medical need. Currently, the company is working on its first investigational Tr1 cell therapy, TRX103, which it plans to evaluate in a Phase 1 trial to prevent Graft versus Host Disease (GvHD) in patients undergoing mismatched hematopoietic stem cell transplant.